Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia

NCT02753894 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT02753894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02753894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Dose Range-finding Study of ASP1585 in Chronic Kidney Disease Patients on Hemodialysis With Hyperphosphatemia
Lead sponsor
Astellas Pharma Inc
Phase
Phase 2
Overall status
Completed
Start date
January 31, 2008
Completion date
June 30, 2008
Enrollment
73 (actual)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

chronic kidney disease patients on hemodialysis with hyperphosphatemia